Search - tctmd.com

Displaying 881 - 900 of 1925

Sort: Relevancy | Date

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Daily News

Surgical Bailout Rarely Needed Though Can Save Lives: TVT Registry

Yael L. Maxwell

September 18, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

Todd Neale

September 13, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

Mortality in Untreated Moderate AS Keeps Pace With What’s Seen in More Severe Disease

L.A. McKeown

September 05, 2019

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31997-X/fulltext

News Conference News ESC 2019

Ten-Year SYNTAXES Results Fix Roles for CABG, PCI in Complex CAD

Shelley Wood

September 05, 2019

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Shelley Wood

September 04, 2019

News Conference News ESC 2019

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

Todd Neale

September 04, 2019

News Conference News ESC 2019

MITRA-FR at 2 Years: Still No Benefit of MitraClip Over Meds

Shelley Wood

September 02, 2019

News Conference News ESC 2019

BMI Not the Best Option for Predicting CV Events, Global Analysis Suggests

Yael L. Maxwell

September 02, 2019

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

Todd Neale

September 02, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Yael L. Maxwell

September 01, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

L.A. McKeown

August 21, 2019

Advertisement

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Surgical Bailout Rarely Needed Though Can Save Lives: TVT Registry

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Mortality in Untreated Moderate AS Keeps Pace With What’s Seen in More Severe Disease

Ten-Year SYNTAXES Results Fix Roles for CABG, PCI in Complex CAD

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

MITRA-FR at 2 Years: Still No Benefit of MitraClip Over Meds

BMI Not the Best Option for Predicting CV Events, Global Analysis Suggests

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content